DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Idiopathic Pulmonary Fibrosis | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2023
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first disease-modifying therapy (DMT)…
Idiopathic Pulmonary Fibrosis | Treatment Algorithms: Claims Data Analysis | US | 2023
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by the thickening and stiffening of tissues in the lungs…
Idiopathic Pulmonary Fibrosis | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2022
Idiopathic pulmonary fibrosis (IPF), one of the most common interstitial lung diseases, is characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first…
Idiopathic Pulmonary Fibrosis | Treatment Algorithms: Claims Data Analysis | US | 2022
MARKET OUTLOOK Idiopathic pulmonary fibrosis (IPF) is a type of lung disease characterized by the thickening and stiffening of tissues in the lungs. While the prognosis for patients diagnosed…
Idiopathic Pulmonary Fibrosis | Treatment Algorithms: Claims Data Analysis | US | 2021
MARKET OUTLOOK Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irreversible loss of lung function,…
Idiopathic Pulmonary Fibrosis | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2020
Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases and is characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first…
Idiopathic Pulmonary Fibrosis | Treatment Algorithms: Claims Data Analysis | US | 2020
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irreversible loss of lung function, leading to high…
Idiopathic Pulmonary Fibrosis | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2019
MARKET OUTLOOK Progress in R&D and technology, regulatory and monetary incentives for advancing the development of treatments for rare diseases, and ongoing focus by the pharmaceutical market…
Idiopathic Pulmonary Fibrosis | Treatment Algorithms: Claims Data Analysis | US | 2019
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irreversible loss of lung function, leading to high…
